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Abstract 
Background: There is considerable interest in positive allosteric modulators (PAMs) of the α-
amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) subtype of ionotropic glutamate 
receptors as therapeutic agents for a range of cognitive and mood disorders. However, the 
challenge is to increase AMPA receptor (AMPAR) function sufficient to enhance cognitive 
function but not to the extent that there are mechanism-related proconvulsant or convulsant side 
effects. In this present study we report the pre-clinical pharmacology data for MDI-222, an 
AMPAR PAM which enhances cognition but has a much reduced side-effect (i.e., convulsant) 
liability relative to other molecules of this mechanism. 
Methods: The pharmacological effects of MDI-222 were characterised in in vitro and in vivo 
preclinical electrophysiology, efficacy (cognition), side-effect (proconvulsant/convulsant), 
tolerability and toxicity assays. 
Results: We demonstrate that MDI-222 is an AMPAR PAM since it enhanced AMPAR function 
in vitro at human (hGluA1-4) and rat (rGluA2) homomeric receptors, and potentiated hetero-
oligomeric AMPARs in rat neurons. MDI-222 enhanced electrically-evoked AMPAR-mediated 
synaptic transmission in the anaesthetised rat at 10 mg/kg (i.v.) and did not significantly lower the 
seizure threshold in the pro-convulsant MEST at any dose tested up to a maximum of 30 mg/kg 
(p.o.). MDI-222 reversed a delay-induced deficit in novel object recognition (NOR) in rats with 
an MED of 0.3 mg/kg (p.o.) following acute administration which was reduced to 0.1 mg/kg 
following sub-chronic administration; improved passive avoidance performance in scopolamine-
impaired rats with an MED of 10 mg/kg p.o. On the other hand, MDI-222 was not proconvulsant 
in the maximal electroshock threshold test (MEST) resulting in a therapeutic window between 
plasma concentrations that enhanced cognitive performance and those associated with mechanism-
related side effects of ≥1000-fold. Unfortunately, despite the excellent preclinical profile of this 
compound, further development had to be halted due to non-mechanism related issues. 
Conclusions: We conclude that MDI-222 is an AMPAR PAM which enhances cognitive 
performance in rats and has a significantly improved safety profile in preclinical species. 
  
There is growing evidence to implicate a dysfunction in glutamate neurotransmission, and the α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) subtype of ionotropic glutamate 
receptors (iGluRs) in particular, in the pathophysiology of a variety of CNS disorders (Chang et 
al., 2012; Lee et al., 2016; Dauvermann et al., 2017). More specifically, AMPA receptors 
(AMPARs) play a critical role in synaptic function since their activation by glutamate results in a 
depolarisation of the postsynaptic membrane which relieves the voltage-dependent Mg2+-blockade 
of N-methyl-D-aspartate receptors (NMDARs; Huganir and Nicoll, 2013). In addition, AMPARs 
are trafficked into and out of the synapse in a use-dependent manner, underscoring the importance 
of these receptors in synaptic plasticity (Henley and Wilkinson, 2016). 
Given their importance in the physiology and pathology of synapses, it is of little surprise that 
AMPARs have attracted considerable attention as potential therapeutic targets (Ward et al., 2010, 
2015; Partin et al., 2015; Reuillon et al., 2016). For example, a reduction in the activity of 
AMPARs by non-competitive antagonists such as talampanel (GYKI 537773, LY300164) and 
perampanel are effective in a variety of preclinical anticonvulsant models, with the latter being 
approved as an antiepileptic drug under the brand name Fycompa (Tsai et al., 2018). On the other 
hand, the well-established role of AMPAR in synaptic plasticity and the nootropic actions of the 
weak AMPA-potentiating effects of aniracetam (Ito et al., 1990; Tang et al., 1991) has resulted in 
the increase in AMPAR function being pursued as a very attractive approach to improving 
cognitive performance in a variety of disorders (Chang et al., 2012). In this regard, a wide range 
of AMPAR positive allosteric modulators (PAMs) have been described of which several from 
Cortex Pharmaceuticals (CX516, CX614, CX691, also known as ORG24448 and Farampator, 
CX717, CX1739) and individual molecules from Eli Lilly (LY451395), Organon (ORG26576), 
Pfizer (PF-04958242), Servier (S18986 and S47445), GSK (GSK729327) and Takeda (TAK-137 
and TAK-653) have entered clinical studies. However, none have yet achieved regulatory approval 
with the development of these various compounds being halted for a variety of molecule- or 
mechanism-specific properties such as short half-life, insufficient potency, poor tolerability or 
inability to dose high enough to achieve sufficient exposure (Buccafusco, 2009; Reuillon et al., 
2016; Purcell et al., 2018). 
One of the primary concerns with modulating AMPAR function is the potential for 
mechanism-related proconvulsant or convulsant liability. Hence, in the same way that negative 
allosteric modulators of AMPARs such as Peramapanel are anticonvulsant, then so potentiating 
AMPARs can promote excitotoxicity and/or seizures. This is of particular concern for the so-called 
Class I (or high-impact) AMPAR PAMs, which alter the kinetics of AMPAR-mediated receptor 
deactivation and desensitization to enhance and prolong synaptic currents (Aria and Kessler, 
2007). On the other hand, Class II (low-impact) AMPAR PAMs only affect deactivation and 
therefore have a much reduced effect on synaptic currents compared to Class I AMPAR PAMs 
(Aria and Kessler, 2007). 
In a previous paper, we described the properties of UoS12258, a Class I AMPAR PAM which 
progressed into clinical studies. In single-dose (0.25-1.75 mg) studies in man this compound had 
a long half-life (c.130 hr) and clinical development was halted due to the risk of drug accumulation 
beyond the limits established by the preclinical convulsant liability in rats, dogs and monkeys 
(Ward et al., 2017). In the present paper, we describe the properties of MDI-222 (Ward et al., 
2011), a back-up compound with a pyrazole chemotype distinct from that of the lead sulphonamide 
compound UoS12258 (Figure 1). Hence, MDI-222 is a Class II AMPAR PAM (Ward et al., 2011) 
that enhances cognition but has a much reduced convulsant liability relative to its predecessor. 
Unfortunately, the preclinical development of this compound was halted due to issues unrelated to 
the AMPAR PAM mechanism. Nevertheless, this compound serves as an example of an AMPAR 
PAM with a much improved safety profile relative to others within this class.  
 
Figure 1. Structure of the AMPAR PAM MDI-222 (1-[4-(1-pyrrolidinylcarbonyl) phenyl]-3-
(trifluoromethyl)-4,5,6,7-tetrahydro-1H-indazole; Compound 9a in Ward et al., 2011). 
 
  
Materials and methods 
The biological assay methods are described in more detail elsewhere (Ward et al., 2017). All 
animal studies were ethically reviewed and carried out in accordance with Animals (Scientific 
Procedures) Act 1986 and the GSK Policy on the Care, Welfare and Treatment of Animals. 
Compound 
MDI-222 (Figure 1) has a molecular weight of 363 and polar surface area of 38 Å² and the 
preparation and preliminary characterization of this compound has been described previously 
(Ward et al., 2011). The compound has generally good brain penetration, with the ratio of brain: 
plasma drug concentrations in the region of 1.5 and has binding to rat, dog, monkey and human 
plasma protein and rat brain protein of ≥99%. The respective plasma half-life and oral 
bioavailability values were 1.4h and 54% in rat and 1.3 h and 18% in dog.   
Intracellular Ca2+ influx assay 
Homomeric human GluA1 flip isoform (hGluA1i), hGluA3i and hGluA4i and rat GluA2i AMPAR 
were all transiently transfected into HEK-293 cells using appropriate DNA constructs (all Q-
unedited in TM2 region to allow Ca2+ permeability) and a lipofectamine 2000 system whereas 
hGluA2i were stably expressed in HEK293 cells. Cells were seeded into 384-well poly-D-lysine-
coated plates) black with a clear bottom; Greiner) at a density of seeding 7500cell/well 2 days 
prior to assay. 
Heteromeric hGluN1A/GluN2B NMDARs were produced by transfection of HEK-293 cells 
with a mixture of hGluN1A-BacMam and hGluN2B-BacMam expression vectors. Cells were 
incubated with 500 µM of the non-competitive NMDAR antagonist ketamine hydrochloride after 
which the BacMam vectors were washed away and cells were plated onto poly-D-lysine coated 
black/clear plates at a density of 20,000 cells/well, again in the presence of 500 µM ketamine, and 
incubated for 24 h prior to the assay. Homomeric hGluK1 kainate receptors were produced by the 
transient transfection of HEK-293 cells with human GRIK1 (Q/unedited) using the lipofectamine 
method. Human GluK2 receptors were stably expressed in HEK cells. Cells were seeded into 384-
well plates at a density of 7,500 cells/well 24 h prior to assay. 
The general method for intracellular Ca2+ measurements was that on the day of the assay, cells 
were washed 3-times with assay buffer (in mM; 20 HEPES, 145 NaCl, 5 KCl, 1 MgCl2, 2 CaCl2, 
5.5 glucose, pH 7.3 with NaOH) after which 20 µL was added to each well. Twenty-µL of Fluo-
4AM were then added to each well (final assay concentration = 2 µM; Molecular Probes) and 
plates were incubated for 60 min in the dark. Cell plates were then washed 3-times to remove 
unloaded Fluo-4 and 30 µL of assay buffer were added to each well, compound added in a 1:3 
serial dilution using a dual 10 µL compound + 10 µL agonist (glutamate, final assay concentration 
= 100 µM) addition protocol. Fluorescence intensity was measured using a Fluorescent Imaging 
Plate Reader (FLIPR) instrument and LY404187 was included in each plate as a reference 
compound. 
Recombinant receptor electrophysiology  
hGluA2 cells were plated onto poly-D-lysine coated microscope slide coverslips (BD Biosciences) 
at a density of 50-75,000 cells/mL and used 1-2 days later. Whole-cell currents were recorded 
using the perforated patch-clamp technique with an EPC9 or EPC10 patch-clamp system and the 
Pulse program (HEKA). External and internal recording solutions comprised (in mM), 140 NaCl, 
2 KCl, 1 MgCl2, 2 CaCl2, 10 glucose and 12 HEPES, pH 7.35 and 150 CsCl, 10 EGTA and 10 
HEPES, pH 7.3, respectively. Patch pipettes had resistances of 2-5 M and solution exchange was 
achieved by using the RSC160 (Biologic) fast perfusion system to produce a rapid application of 
glutamate. Cells were clamped at -60 mV and the current induced by a 2 s application of agonist 
was recorded and agonist application was repeated every 30 s. in the absence or presence of test 
compound. Compound responses were related to the current produced by 1 mM alone. 
Native receptor electrophysiology 
Embryonic rat brains were harvested following sacrifice of the pregnant female by CO2 inhalation. 
The dissected hippocampi were placed into ice-cold medium comprised of: Hank’s Balanced Salt 
Solution (HBSS; Ca2+- and Mg2+-free); pyruvate, 1 mM; penicillin, 100 mg/mL; streptomycin, 
100 mg/mL; HEPES, 10 mM; NaHCO3, 0.035% and tissue was then trypsinised for 30 min at 37 
C in trypsin/EDTA diluted (final concentration 0.05%) in HBSS with sodium pyruvate (Ca2+- and 
Mg2+-free). Tissue pieces were physically dissociated and neurons were plated onto poly-D-lysine 
coated coverslips in plating medium (Neurobasal Medium + 1 mM sodium pyruvate; penicillin, 
100 mg/mL; streptomycin, 100 mg/mL; B27 supplement 1x; L-glutamine, 1 mM) and cells were 
used for recordings after 5 to 13 days in culture. 
Whole-cell voltage-clamp recordings from rat cultured hippocampal neurons were made using 
standard methods and an Axopatch 200B amplifier and pClamp 8.0 software (Axon Instruments) 
with cells being held at -70 mV throughout. Solution exchange was achieved using a fast-step 2 
tube perfusion system (Biologic  RSC 160). Inward currents induced by AMPA application were 
complex in that their magnitude and duration depended on three different mechanisms: (1) opening 
of the AMPA receptor channel measured in terms of peak amplitude, (2) desensitization of AMPA 
receptors measured as the degree of relaxation of the inward current from its initial peak amplitude 
to a reduced steady state plateau level in the continued presence of AMPA and (3) deactivation of 
AMPA receptors measured as the rate at which the inward current decayed back to baseline 
following termination of the AMPA application. For each of these parameters, the effects of MDI-
222 were compared to the effects of AMPA alone. 
In vivo electrophysiology 
Surgery was performed on adult male Lister hooded rats (240-340 g) under isoflurane anaesthesia 
and involved cannulating the jugular vein using Portex tubing such that the cannula projected 
externally from the animal. Each rat was then placed in a stereotaxic frame with body temperature 
being maintained using a thermostatically-controlled heated blanket and rectal probe. A midline 
incision was made to expose the dorsal aspect of the skull and a burr hole made to allow 
implantation of a concentric bipolar stimulating electrode (World Precision Instruments™) into 
the medial perforant pathway (from Lambda: AP 0 mm, ML 4.0-4.2 mm, DV ~2.5-2.8 mm). A 
small craniotomy was made and the dura reflected to allow a tungsten recording electrode (0.1 
MΩ, World Precision Instruments™) to be implanted into the ipsilateral dentate gyrus (from 
Bregma: AP -3.6 mm, ML 2.0-2.55 mm, DV ~2.5-3.0 mm).  
Recordings were made with reference to a silver ground electrode placed under the skin 
margin and potentials were amplified and filtered using a Neurolog™ extracellular AC recording 
system (gain 200; filters 0.1 Hz to 3 kHz). A linear constant stimulus isolator driven by Spike2 
software and a CED pulse shaper was used to deliver electrical stimuli (<50% maximum; duration 
90-200 µs) through the concentric bipolar stimulating electrode at either 0.1 or 0.03 Hz. Stable 
field excitatory postsynaptic potentials (fEPSPs) and superimposed population spikes were 
recorded in response to each stimulus with a paired-pulse stimulation paradigm being used to 
verify electrode placement. Once stable responses were established, a baseline set of responses 
was recorded for a 20 min period after which vehicle (99% PEG200/1% DMSO doses at 1 mL/kg) 
or MDI-222 were administered via the jugular vein cannula and recordings made for a 20 min 
period.  The study was then terminated and blood and brain samples were collected and frozen at 
-80oC prior to subsequent analysis of drug concentrations using liquid chromatography/tandem 
mass spectrometry (LC-MS/MS) using a Quattro Premier (Micromass) mass spectrometer with 
positive-ion electrospray ionisation. 
Novel object recognition 
Rats were habituated to Perspex test arenas (42 cm length x 21 cm wide x 20 cm high) for 60 min 
(am) and 3 min (pm) on two consecutive days prior to testing. Rats were sham dosed with vehicle 
prior to both 1 h habituation sessions. On the first test day, rats were placed in a test arena for a 3 
min habituation period and then presented with 2 identical objects (T1, 3 min). 24 h later rats were 
placed back in the test arena and presented one of the previous (familiar) objects and a novel object 
(T2, 3 min). Objects used were similar sized black plastic tower and pyramid shapes 
(approximately 6.5 cm high x 6 cm wide). Objects were cleaned with 70% ethanol between 
animals to remove any odour trace. The novel object and novel object side (left or right) was 
randomised equally across all treatment groups. The time spent exploring the objects during T1 
and T2 was recorded by an observer blind to the novel object. 
Rats (n=12/group) received MDI-222 or vehicle (1% methylcellulose) by oral gavage (p.o.) 
unless stated otherwise. For the acute study MDI-222 was administered at 0.1, 0.3, 1 and 3 mg/kg 
p.o. 30 min prior to testing in both T1 and T2 sessions. For the sub-chronic study MDI-222 was 
administered at 0.03, 0.1, 0.3 and 1 mg/kg p.o. once daily for 7 days and then 30 min prior to T1 
and T2 sessions on days 8 and 9 respectively. Immediately after T2 behavioural testing, rats (n = 
3 for all treatment groups) were culled and blood and brains taken for pharmacokinetic analysis as 
described previously. 
The key parameters derived from the NOR assay are the T1 and T2 times, which are the total 
time spent exploring both objects during Trial 1 and Trial 2, respectively. The D1 index is the time 
spent exploring the novel object during Trial 2 minus the time spent exploring the familiar object 
during Trial 2 whereas the D2 index is the D1 index/total exploration time during Trial 2 (T2). Of 
these different parameters, the D2 index is used as the primary indicator of an ability to 
“remember” the objects experienced during Trial 1. Hence, a larger D2 index in drug-treated 
relative to vehicle-treated animals represents an increased ability to “remember” the objects 
experienced during Trial 1. 
Passive avoidance 
The passive avoidance task (PA) records the ability of animals to remember an aversive stimulus. 
Performance is impaired by post-training treatment with the muscarinic antagonist, scopolamine.  
Male Wistar rats were pre-treated with MDI-222 30 min prior to training (3, 10 and 30 mg/kg, p.o. 
in 25% labrasol, n = 6). Scopolamine (1 mg/kg, i.p.) was administered 6 h post training. Task recall 
was assessed 24 h post training in the absence of drug. 
Maximal electroshock threshold (MEST) test 
Half an hour before testing, male Lister Hooded rats (118-145 g; n=12/group) received i.p. 
injections of either saline or the known pro-convulsant, picrotoxin (2 mg/kg i.p.), or p.o. doses of 
either vehicle (1% methylcellulose) or 3, 10 or 30 mg/kg MDI-222.  During the testing phase, the 
induction of a tonic hind limb extensor seizure was assessed following a 0.1 second shock 
administered via corneal electrodes according to the 'up and down' method (Kimball et al., 1957).  
A separate (satellite) group of animals (n=2/3 per dose) were dosed and blood and brain samples 
taken at the appropriate pre-treatment time for analysis of compound. 
 
 
Results  
MDI-222 potentiates Ca2+ flux in recombinant homomeric AMPARs 
In cells stably-expressing hGluA2 AMPAR, the application of glutamate (100 µM) alone did not 
elicit a signal due to rapid AMPAR desensitisation. However, in the presence of MDI-222, the 
application of glutamate consistently increased intracellular Ca2+ levels to a maximum extent (123 
± 7%) comparable to the positive control (LY404187; Table 1). The effect of MDI-222 in hGluA2 
AMPAR was concentration-dependent and had a pEC50 of 5.3 (EC50 = 5.0 µM) that was 
comparable to UoS12258 (pEC50 = 5.19, EC50 = 6.5 µM; Ward et al., 2017). 
Table 1. Potentiation by glutamate-induced Ca2+ flux in homomeric assemblies of different 
AMPAR subtypes 
AMPAR subtype pEC50 (n) Max. % response (n) 
a 
hGluA1i b 4.6, 4.7  (2)  30 ± 2 (4) 
hGluA2i 5.3  0.1 (9) 123  7 (9) 
hGluA3i 4.5 ± 0.1 (3) 53 ± 3 (3) 
hGluA4i 5.1 ± 0.1 (4) 76 ± 1 (4) 
rGluA2i 5.4 ± 0.1 (4) 76 ± 8 (4) 
a, the maximum response is defined in terms of the positive control LY404187 
b, MDI-222 was tested 4 times and gave a consistent max response (30 ± 2%) but in only 2/4 assays was it 
possible to reliably calculate pEC50 values. 
Values shown are mean ± standard error of the mean  
 
MDI-222 had comparable effects at all four homomeric human AMPAR subtypes (i.e., 
GluA1, GluA2, GluA3 and GluA4) and showed no marked differences between the rat and human 
GluA2 AMPARs (Table 1). There were no effects of MDI-222 on glutamate-induced currents in 
cell lines expressing either GluN1A/GluN2B-containing NMDARs or GluK1 or GluK2 kainate 
receptors measured either using the Ca2+ flux assay or whole-cell patch clamp electrophysiology 
(data not shown). The selectivity of MDI-222 for AMPAR was further emphasized by the fact that 
when tested at a concentration of 10 µM, it demonstrated no significant binding to a panel of 79 
different receptors, ion channels and transporters (CEREP).    
MDI-222 potentiates whole-cell glutamate-induced currents in hGluA2 AMPARs 
The functional effects of MDI-222 on hGluA2 AMPARs were further assessed using whole-cell 
voltage-clamp electrophysiology to measure potentiation of inward currents evoked by 1 mM 
glutamate (Figure 2). MDI-222 significantly potentiated glutamate-evoked charge transfer (area 
under the curve) by 121   7% (P<0.05 paired t-test, n = 9) at 100 nM and 702  40% at 10 µM 
(P<0.05, paired t-test, n = 3). 
 
Figure 2. Representative traces showing glutamate (1 mM)-induced currents recorded in the absence and 
presence of 100 nM and 10 µM MDI-222 (100 nM and 10 µM) in HEK cells stably expressing human 
GluA2 receptors. 
 
MDI-222 potentiates AMPAR-mediated responses in native rat AMPARs 
The effect on native neuronal AMPARs was assessed by measuring the effects of 1 nM to 10 μM 
MDI-222 on AMPA-induced whole cell currents (30 μM, 2 s pulses every 30 s) recorded from rat 
cultured hippocampal neurons. Representative current traces from a neuron incubated with AMPA 
alone or AMPA plus 10 nM or 10 μM MDI-222 are overlaid in Figure 3.. The potentiation of 
AMPA-induced currents was quantified in terms of the effects of MDI-222 on total charge transfer 
(essentially the area under the curve), and the rates of desensitisation and deactivation. These 
parameters are summarised in Table 2 which clearly shows a significant but modest effect on 
charge transfer and desensitisation at minimum effective concentrations of 1 and 10 nM, 
respectively. However, there was no effect on deactivation except at the highest concentration 
tested (10 µM). As regards total charge transfer, 10 µM MDI-222 gave only a modest (62%) 
increase in the charge transfer.  
 
Figure 3. Representative traces showing the potentiation of a 30 µM AMPA-induced current by 10 nM and 
10 µM MDI-222 in cultured isolated rat hippocampal neurons. Importantly, when applied in the absence of 
AMPA, MDI-222 did not invoke an inward current, indicating that it needed the presence of agonist to be 
effective. 
 
Table 2. Effects of MDI-222 on various aspects of the AMPA-mediated inward current 
measured in isolated rat hippocampal neurons 
 Conc. MDI-222 
(no. of cells) 
       Responses, normalised to 30 µM AMPA alone 
Charge transfer Desensitisation  Deactivation 
1 nM (5)  1.14 ± 0.05 *  0.77 ± 0.10   1.06 ± 0.04 
10 nM (4)  1.37 ± 0.09 *  0.81 ± 0.05 *  1.19 ± 0.15 
100 nM (4)  1.33 ± 0.12 *  0.76 ± 0.03 *  1.29 ± 0.17 
1 µM (4)  1.28 ± 0.14 *  0.72 ± 0.04 *  1.33 ± 0.17 
10 µM (9)  1.62 ± 0.15 *  0.25 ± 0.08 *  2.79 ± 0.43 * 
*, Statistically significant changes compared to AMPA alone (* P<0.05 paired t-test). 
Values shown are mean ± standard error of the mean. 
 
10 µM
10 nM
30 µM AMPA
MDI-222
MDI-222 potentiates the dentate gyrus population spike amplitude in anaesthetised rats 
In order to demonstrate that MDI-222 could modulate electrophysiological activity in vivo, 
anaesthetised rats were given either 3 or 10 mg/kg compound i.v. and the amplitude of the 
electrically-evoked dentate gyrus population spike was measured. Figure 4 shows that a 10 (but 
not 3) mg/kg i.v. dose of MDI-222 was able to significantly increase population spike amplitude 
from 70% of baseline in the vehicle-treated animals to 139% of baseline (P<0.05, n=3). Analysis 
of brain samples taken immediately after the experiment showed mean brain drug concentrations 
of 11.6 µg/g.  
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Figure 4. MDI-222 (10 mg/kg i.v.) was able to increase the amplitude of the electrically-evoked population 
spike recorded in the dentate gyrus of anaesthetised rats (the 30% reduction in amplitude within the vehicle 
group relative to baseline is presumed to be related to the i.v. injection). Veh. = vehicle (99% PEG200/1% 
DMSO). Values shown are mean ± standard error of the mean (n=3/group). 
 
Novel object recognition 
Two separate acute, single-dose administration studies of the effects of MDI-222 in the novel 
object recognition assay were conducted. In Experiment 1, doses of 0.1, 0.3 and 1 (but not 3) 
mg/kg p.o. MDI-222 resulted in a significant increase in the time spent exploring the novel relative 
to familiar objects (Figure 5A, left-hand panel). This translated into a significant increase the D2 
index at 0.3 and 1 mg/kg (but not 0.1 or 3) mg/kg (Figure 5A, right-hand panel). In Experiment 2, 
p.o. doses of 0.3, 1 and 3 mg/kg all produced a significant increase both in the exploration of the 
novel relative to familiar object as well as the D2 index (Figure 5B).  At the minimal effective 
dose for the D2 index of 0.3 mg/kg, the respective mean blood and brain drug concentrations were 
9 ng/mL and 16 ng/g for Experiment 1 and 25 ng/mL and 37 ng/g for Experiment 2, with the 
differences between experiments presumably reflecting a variability in the formulation of the 
compound that was a consequence of its poor solubility. 
When administered sub-chronically for 7 days, MDI-222 significantly increased the 
exploration of the novel versus familiar object at doses of 0.1, 0.3 and 1 mg/kg p.o. with these 
same three doses also significantly increasing the D2 index (Figure 5C). At the minimally effective 
dose of 0.1 mg/kg, mean blood and brain levels were 7 ng/mL and 9 ng/g, respectively. 
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Figure 5. MDI-222 enhanced performance in the novel object test of recognition memory. A. (Experiment 
1) and B (Experiment 2). After acute (single) doses, 0.3 and 1 mg/kg p.o. MDI-222 significantly increased 
the time spent exploring the novel compared to familiar object (left-hand panel) as well as the D2 index 
(right hand panel). C. MDI-222 also improved performance following sub-chronic (7-day) dosing, with the 
minimal effective dose being 0.1 mg/kg p.o. Values shown are mean ± SEM (n=11/18/group). *, ** = 
P<0.05 and 0.01 for within group exploration of familiar versus novel object (left-hand panels) or D2 index 
score relative to vehicle-treated animals (right-hand panels). 
 
MDI-222 reverses a scopolamine-induced deficit in passive avoidance 
Compared to vehicle-treated animals, scopolamine (1 mg/kg i.p.) produced a much shorter latency 
for rats to step through from the safe to the aversive chamber (Figure 6; respective latencies for 
vehicle- and scopolamine-treated rats = 457 ± 83 and 157 ± 46 s), indicating that scopolamine 
impairs the “remembering” of the conditioning trial on Day 1. Doses of 10 and 30 mg/kg p.o. 
MDI-222 were able to significantly reverse the scopolamine-induced deficit. These effects could 
not be attributed to changes in exploratory behaviour since on either the training or recall day, 
activity in the open field was not altered by drug treatment (data not shown). Accordingly, in this 
assay, the MED of MDI-222 was 10 mg/kg p.o.  
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Figure 6. MDI-222 reversed a scopolamine-induced deficit in performance in the rat passive avoidance 
assay. Vehicles used were saline (scopolamine, given i.p.) and 1% methyl cellulose (MDI-222). Values 
shown are mean ± standard error of the mean (n=6/group). *, P<0.05 versus the veh. + scopolamine group. 
 
MDI-222 is not proconvulsant in the maximal electroshock seizure threshold (MEST) test 
In the MEST test, corneal application of electrical current (CC50 approx. 60-70 mA, 0.1 ms 
duration) in the rat induces tonic and full tonic-clonic seizures. As expected, the GABAA receptor 
blocker picrotoxin produced a robust proconvulsant effect, reducing the CC50 by almost half 
relative to saline-treated controls (CC50 values of 49 ± 8 and 26 ± 1 for saline and picrotoxin-
treated animals respectively; Figure 7). In contrast, MDI-222 did not significantly affect the seizure 
threshold, with CC50 values (53 ± 2, 51 ± 4 and 52 ± 2 at 3, 10 and 30 mg/kg p.o., respectively) 
being between 10-15% lower than vehicle (1% methylcellulose)-treated rats (CC50 = 60 ± 4). This 
lack of effect of MDI-222 was despite excellent brain exposures (measured in a satellite group of 
animals), with the highest dose tested, 30 mg/kg p.o., resulting in brain drug concentrations of 
around 4,700 ng/g.  
 Figure 7: MDI-222 does not reduce seizure threshold in the maximal electroshock seizure threshold test. 
MDI-222 was dosed orally in a 1% methylcellulose vehicle with a pre-treatment time of 0.5 h prior to 
testing. In these studies, the effects of picrotoxin (Ptx, 2 mg/kg i.p.) versus animals treated with saline (Sal) 
were used as a positive control. Values shown are mean ± standard error of the mean (n=12/group) with a 
satellite group of animals (n=2-3/dose) being dosed in order to generate blood and drug concentrations. **, 
P <0.01 compared to vehicle-treated animals. 
 
 
Discussion 
MDI-222 is a relatively weak and non-selective potentiator of the human AMPAR as measured 
using the Ca2+ flux assay (pEC50 values ranging from 4.5 to 5.4 across the hGluA1, hGluA2, 
hGluA2 and hGluA2 subtypes). Moreover, there were no human-to-rat species differences since 
the pEC50 values of MDI-222 at hGluA2 and rGluA2 were comparable (pEC50 values of 5.3 and 
5.4, respectively). The compound did not have activity at other members of the ionotropic 
glutamate receptor (iGluR) family, demonstrating no effects on GluN1a/GluN2B heteromeric 
NMDARs or homomeric GluK1 or GluK2 receptors in either the Ca2+ flux or electrophysiological 
assays. In addition, MDI-222 did not bind a panel of 70 different receptors, ion channels and 
transporters, further emphasising its selectivity for AMPARs. MDI-222 was the back-up 
compound to the lead molecule UoS12258 (Ward et al., 2017). This latter compound was also a 
relatively weak AMPAR PAM, having a pEC50 of 5.6 in both the Ca
2+ flux and whole-cell patch 
clamp assays but was much more potent that MDI-222, with, for example, the maximal 
potentiation in the charge transfer (i.e., area under the curve) in rat primary hippocampal neurons 
being 62% for MDI-222 (Table 2) and 310% for UoS12258 (Ward et al., 2017). 
The apparently modest in vitro AMPA PAM efficacy of MDI-222 nevertheless translated into a 
significant functional effect in vivo in that MDI-222 was able to potentiate the dentate gyrus 
population spike amplitude in anaesthetised rats (Figure 3) and enhanced cognitive performance 
in the NOR assay, with minimum effective doses of 0.3 and 0.1 mg/kg p.o. when dosed acutely 
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and sub-chronically, respectively (Figure 4). The MED for MDI-222 in the acute-dosing NOR 
assay is the same as that obtained for the “more potent” UoS12258 (0.3 mg/kg p.o.). However, the 
MED of UoS12258 in the NOR following sub-chronic dosing (0.01 mg/kg p.o.; Ward et al., 2017) 
was appreciably lower than that seen with MDI-222 (0.1 mg/kg p.o.). On the other hand, in the rat 
passive avoidance assay, both MDI-222 and UoS12258 were able to reverse a scopolamine-
induced deficit with similar MED values (10 and 3 mg/kg p.o., respectively). Hence, despite their 
differences in intrinsic efficacy, both MDI-222 (a low-impact AMPAR PAM) and UoS12258 (a 
high-impact AMPAR PAM) have a broadly similar potency with respect to cognitive 
enhancement. In contrast, the compounds had markedly different effects in the MEST assay of 
proconvulsant activity. Hence, MDI-222 had no effect on the seizure threshold, even at a dose (30 
mg/kg p.o.) that gave excellent brain exposure with drug concentrations of approximately 4.7 µg/g 
(Figure 7).  In contrast, UoS12258 produced a marked reduction in the threshold such that at a 
dose (100 mg/kg p.o.) giving a brain exposure of around 5.0 µg/g, the proconvulsant effect was 
comparable to that of the positive control picrotoxin (Ward et al., 2017). 
Despite possessing a proconvulsant activity in the MEST assay UoS12258 progressed into 
preclinical and clinical development, since at the time this was considered to be an inherent, 
mechanism-related side effect that could not be separated out from the cognition-enhancing 
effects. Furthermore, in 6-week GLP preclinical Safety and Toxicity studies, UoS12258 
demonstrated convulsant activity in all three species studied (rat, dog and cynomolgus monkey) 
with the no adverse effect levels being defined at 2.5 and 3 mg/kg p.o. for cynomolgus monkey 
and rat, respectively (Figure 8). Thereafter, UoS12258 was evaluated in single-dose (0.25-1.75 
mg) Phase 1 studies in man where further development was halted due to a prolonged half-life 
(~130 h), which raised the possibility of drug accumulation to levels beyond those considered 
acceptable from a safety point of view. 
 
 Figure 8. Comparison of the preclinical safety profiles showing the much safer profile of MDI-222 
compared to UoS12258. A. MDI-222 was not proconvulsant in the maximal electroshock threshold test 
(MEST) assay at a dose of 30 mg/kg p.o. and neither did it cause convulsions during 7-day dose ranging 
studies (maximum doses in rat and dog = 1,600 and 1,000 mg/kg p.o., respectively) or 4-week GLP Safety 
and Toxicity studies (maximum doses in rat and dog = 800 and 1,000 mg/kg p.o., respectively). To 
overcome solubility-limiting sub-proportional concentrations at higher doses, 14-day exploratory toxicity 
studies were conducted using a nanomilled formulation.  In plasma drug concentrations equivalent to a dose 
of ~2,000 mg/kg of the standard formulation, convulsions were observed.  B. UoS12258 was proconvulsant 
in the MEST assay at a dose of 10 mg/kg p.o. (data not shown for clarity; Ward et al., 2017) and during 
dose-range finding studies caused convulsions in dogs, cynomolgus (cyno.) monkeys and rats at doses of 
3, 9 and 10 mg/kg p.o., respectively. Because of the sensitivity of dogs, the cynomolgus monkey was chosen 
as the second species, along with rat, for 6-week GLP Safety and Toxicity studies in which convulsions 
were observed at doses of 4 and 10 mg/kg in cynomolgus monkeys and rats, respectively with the no adverse 
effect levels (NOAEL) being 2.5 and 7.5 mg/kg, respectively. For both compounds, the efficacy assay used 
to define the therapeutic margin was the novel object recognition (NOR) assay. Doses shown are mg/kg 
p.o. 
 
In contrast to UoS12258, MDI-222 had a much more benign preclinical safety profile. Specifically, 
and consistent with its lack of a proconvulsant liability in the MEST assay, in 7-day dose-range 
finding study, doses of up to 1,600 mg/kg in rat (corresponding to plasma Cmax concentrations of 
around 15,000 ng/mL) and 1,000 mg/kg in dog (4-8,000 ng/mL, depending on gender) were well 
tolerated and did not produce convulsions (Figure 8). There were also no convulsions observed in 
the subsequent 4-week, GLP safety assessment studies in both rat or dog even at the highest doses 
tested (800 mg/kg in rat and 1,000 mg/kg in dog, corresponding to respective plasma Cmax 
concentrations of 13-17,000 and 8-13,000 ng/mL). 
During the 4-week safety assessment studies, systemic exposures on Day 28 relative to Day 1 
were up to 6-fold lower in rat and 9-fold lower in dog, and non-dose-proportional systemic 
concentrations were observed at elevated doses. To improve systemic concentrations and 
investigate the potential metabolic induction, an additional 14-day exploratory toxicity 
investigation was conducted. In these studies, dogs were dosed with a nanomilled formulation of 
MDI-222 that produced a plasma exposure (Cmax = 23,000 ng/mL) equivalent to around 2,000 
mg/kg of the “standard” formulation and convulsions were observed. 
Given that the minimal effective dose of MDI-222 in the NOR assay is either 0.3 mg/kg p.o. 
when dosed acutely (corresponding to plasma drug concentrations of 9 and 25 ng/mL in Expts. 1 
and 2, respectively) or 0.1 mg/kg p.o. when given sub-chronically (plasma concentration = 7 
ng/mL), then there is a very large, ≥1,000-fold therapeutic index between plasma concentrations 
required for efficacy (7-25 ng/mL) and those shown to cause convulsions in dogs (23,000 ng/mL). 
Despite this very attractive safety profile, further development of MDI-222 was halted due to non-
mechanism-related developability issues. These included poor solubility, high protein binding and 
an activation of the pregnane X receptor linked to a potential for drug-drug interactions. 
In summary, MDI-222 is an AMPAR PAM which produced cognition enhancing effects in 
rats with a significantly improved tolerability profile over its predecessor UoS12258 and other 
molecules of this class. Although further development of MDI-222 was not possible, these studies 
nevertheless demonstrate the feasibility of dissociating the desirable cognition enhancing effects 
from the unwanted proconvulsant or convulsant liabilities that are often considered to be inherent 
in compounds that enhance AMPAR-mediated neurotransmission. The dissociation between the 
cognition enhancing and proconvulsant/convulsant effects as a consequence of increasing 
AMPAR function has recently been also demonstrated with additional compounds (Kunugi et al., 
2019) and suggests that the therapeutic potential of AMPAR PAMs may finally achieve clinical 
utility, not only in diseases associated with cognitive dysfunction, but also other disorders 
associated with a dysfunction of glutamatergic neurotransmission and more specifically AMPARs, 
such as depression (Zanos et al., 2016). 
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